Jpmorgan Chase & CO Tenaya Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 24,161 shares of TNYA stock, worth $58,228. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,161

Previous 18,929 27.64%

Holding current value

$58,228

Previous $98,000 24.49%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$2.72 - $4.99 $14,231 - $26,107	5,232 Added 27.64%	24,161 $74,000
Q1 2024 May 10, 2024	SELL	$2.88 - $6.8 $31,469 - $74,303	-10,927 Reduced 36.6%	18,929 $98,000
Q4 2023 Feb 12, 2024	SELL	$1.73 - $3.39 $13 - $27	-8 Reduced 0.03%	29,856 $96,000
Q3 2023 Nov 14, 2023	SELL	$2.55 - $5.65 $14,843 - $32,888	-5,821 Reduced 16.31%	29,864 $76,000
Q2 2023 Aug 11, 2023	BUY	$2.64 - $7.64 $2,684 - $7,769	1,017 Added 2.93%	35,685 $209,000
Q1 2023 May 18, 2023	BUY	$1.92 - $3.59 $63,684 - $119,076	33,169 Added 2212.74%	34,668 $98,000
Q1 2023 May 11, 2023	SELL	$1.92 - $3.59 $30,370 - $56,786	-15,818 Reduced 91.34%	1,499 $4,000
Q4 2022 Feb 13, 2023	BUY	$1.68 - $3.19 $35 - $66	21 Added 0.12%	17,317 $35,000
Q3 2022 Nov 14, 2022	BUY	$2.9 - $5.88 $1,789 - $3,627	617 Added 3.7%	17,296 $50,000
Q2 2022 Aug 11, 2022	SELL	$5.01 - $14.12 $26,036 - $73,381	-5,197 Reduced 23.76%	16,679 $94,000
Q1 2022 May 11, 2022	BUY	$9.41 - $19.3 $90,778 - $186,187	9,647 Added 78.89%	21,876 $258,000
Q4 2021 Feb 10, 2022	BUY	$18.41 - $29.58 $101,310 - $162,778	5,503 Added 81.82%	12,229 $232,000
Q3 2021 Nov 12, 2021	BUY	$15.35 - $26.66 $103,244 - $179,315	6,726 New	6,726 $139,000

Others Institutions Holding TNYA

# of Institutions

Shares Held

56.1M

Call Options Held

30.3K

Put Options Held

600

View Full List

About Tenaya Therapeutics, Inc.

Ticker TNYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,364,700
Market Cap $99.7M
Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...

More about TNYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Tenaya Therapeutics, Inc. Transaction History